

The relationship between human MAT1A mutations and disease: a folding and association problem?

María A. Pajares^{1*} and Claudia Pérez^{1,2}

¹Instituto de Investigaciones Biomédicas “Alberto Sols” (CSIC-UAM), Arturo Duperier 4, 28029 Madrid, Spain.

²Now at: Instituto de Biotecnología. Universidad Nacional Autónoma de México, 62250 Cuernavaca, Morelos, México.

*Author to whom correspondence should be addressed at: Instituto de Investigaciones Biomédicas “Alberto Sols” (CSIC-UAM), Arturo Duperier 4, 28029 Madrid, Spain. (Phone: 34-915854414; FAX: 34-915854401; email: mapajares@iib.uam.es)

Keywords: S-adenosylmethionine, methionine adenosyltransferase, human mutations, oligomerization.

Abbreviations: MAT, methionine adenosyltransferase; AdoMet, S-adenosylmethionine; GSH, glutathione reduced form; GSSG, glutathione oxidized form; AdoHcy, S-adenosylhomocysteine; Hcy, homocysteine; CBS, cystathionine β -synthase; MTHF, 5-methyltetrahydrofolate; MTHFR, methylenetetrahydrofolate reductase; NO, nitric oxide; PKC, protein kinase C.

ABSTRACT

Methionine adenosyltransferases (MATs) are a family of highly conserved oligomers that catalyze the only known reaction for the synthesis of S-adenosylmethionine (AdoMet), the main cellular methyl donor. Their catalytic subunits exhibit a characteristic structure, organized in three domains formed by nonconsecutive stretches of the sequence. The active sites locate at the interface between subunits in the dimer with amino acids of each monomer contributing to catalysis. Changes in activity, oligomerization level and expression have been detected in several hepatic diseases; the knockout mouse for *MAT1A* spontaneously developing hepatocellular carcinoma (HCC). However, none of the patients with persistent hypermethioninemia caused by mutations in this gene exhibits hepatic problems, instead a few cases showing demyelination have been described. This chapter discusses aspects related to the structural features of these enzymes and the impact that the mutations found in the human *MAT1A* gene may have in the final protein structure. The influence of the redox environment in MAT folding and association is also analyzed, in light of the effects that drugs and metals that alter the GSH/GSSG ratio produce in the activity and association level. The recent report of the nuclear localization of the MAT I/III isoenzymes, along with their presence in tissues other than liver opened the option to MAT moonlighting. The possibility exists that disease development is related not only to a decrease in AdoMet production, but also to the role of these particular isoenzymes in different subcellular compartments. Therefore, the influence of *MAT1A* mutations, especially those leading to protein truncations, on folding and subcellular localization is discussed, paying special attention to the Hazelwood's hetero-oligomerization hypothesis to explain the demyelination process in patients with persistent hypermethioninemia.

1. Introduction

The first mention of an “active methionine” capable of transmethylation in the absence of ATP was made in 1951 by Giulio L. Cantoni in a paper where the biosynthesis of N^1 -methylnicotinamide from methionine and nicotinamide was studied [1]. The nature of this compound was ignored at that moment, although it was described as a product resulting from the reaction between ATP and methionine. In 1953, a new paper by this author described the reaction catalyzed by the “methionine-activating enzyme” and the chemical nature of the “active methionine”, S-adenosylmethionine (AdoMet)[2]. This compound was defined as an addition product of methionine and the adenosine moiety of ATP, having the configuration of a sulfonium compound in which an energy-rich bond links the methyl and the onium groups. This sulfonium ion is also involved in carbon-sulfur bonds with two additional groups, the 3-amino-3-carboxypropyl and 5'-deoxyadenosyl groups that can be donated as well. In the three cases donation of either of these groups requires the nucleophilic attack of the corresponding carbon-sulfur bond [3, 4]. Additionally, AdoMet can provide other groups for the synthesis of biological compounds (Figure 1), a fact that favors its implication in a large variety of reactions. Such a versatility let authors calculate that the number of reactions in which this donor participates is as large as that involving the use of ATP [5].

Methylation reactions are of special importance due to the large number of such processes that take place in any cell, and that result in the main consumption of AdoMet (~90-95%). These processes serve either for the synthesis of new compounds (methylation of small molecules, phospholipids, etc.) or for the regulation of cell function (methylation of DNA, RNA or proteins), and in all cases S-adenosylhomocysteine (AdoHcy) is produced [6]. AdoHcy is a potent inhibitor of most transmethylation reactions, but serves also as the intermediate for the synthesis of homocysteine (Hcy) and an important bacterial signaling molecule, Autoinducer-2 [7]. The aminocarboxypropyl group of AdoMet can be donated for the synthesis of the hypermodified tRNA nucleoside 3-(3-amino-3-carboxypropyl) uridine [8], but previous decarboxylation at this group is required for aminopropyl donation for the synthesis of polyamines (spermidine and spermine in mammals), plant hormones (ethylene), or signal molecules of Gram negative bacteria (N-acyl-L-homoserine lactones) [9]. Recently, a new class of proteins collectively named as SAM radical proteins was uncovered [10]. This family of enzymes uses the 5'-deoxyadenosyl

radical of AdoMet for the synthesis of vitamins (biotin), antioxidants (lipoic acid) and photosynthetic pigments. Other uncommon reactions involving AdoMet include the donation of amino groups for the synthesis of 7,8 pelargonic acid (a precursor of biotin) [11], ribosyl groups for queuosine synthesis [12], and carboxylic groups to lipophilic acceptors [13]. AdoMet has also been shown to undergo biohalogenation reactions leading to 5'-deoxy-5'-fluoroadenosine or its chloro-, bromo- or iodo- analogues [9].

AdoMet has additional roles as regulator of its own production and elimination through its effects on several enzymes of the methionine and the folate cycles, as well as in the trans-sulfuration pathway. In mammals, the essential amino acid methionine is mainly metabolized in the liver (~48% of the ingested amino acid in humans), where it can be used either for protein synthesis or by the methionine cycle (Figure 2). The first and rate-limiting step in this last pathway is AdoMet synthesis catalyzed by the methionine adenosyltransferase (MAT) isoenzymes, some of which are inhibited by the product. In human adult liver up to 8 g of AdoMet are produced by MATs daily [14], most of which is used as methyl donor for the transmethylation reactions leading to AdoHcy generation. This compound is metabolized by AdoHcy hydrolase leading to Hcy and adenosine, the only reversible step of the cycle that favors AdoHcy accumulation. Thus, elimination of the products of this reaction, Hcy and adenosine, controls the levels of this transmethylation inhibitor. Four are the enzymes involved in this removal: i) adenosine deaminase that transforms adenosine into inosine; ii) cystathionine β -synthase (CBS) that uses Hcy and serine in a condensation reaction to render cystathione, a step that is activated by AdoMet; iii) methionine synthase that remethylates Hcy using as methyl donor 5-methyltetrahydrofolate (MTHF); and iv) betaine homocysteine methyltransferase that remethylates Hcy utilizing as methyl donor the betaine provided by choline oxidation, in a step inhibited by AdoMet [15]. These reactions allow connection of methionine metabolism with other pathways such as trans-sulfuration through the CBS reaction and the folate cycle that includes methionine synthase. The trans-sulfuration pathway renders cysteine that is used among others for protein and glutathione synthesis, the GSH/GSSG ratio modulating MAT activity [16]. Folate recycling is also controlled by AdoMet, which inhibits methylenetetrahydrofolate reductase (MTHFR), and hence MTHF production. This last compound is also an inhibitor of glycine-N-methyltransferase, the transmethylating enzyme responsible of the largest

consumption of AdoMet in a key step for controlling the levels of this metabolite [17]. In addition to these data, AdoMet has been also involved in the regulation of several processes, among them apoptosis and growth [18]. The role exerted in apoptosis (protector or inducer) depends on the cell type under study (hepatocytes or hepatoma cells) and can be mimicked by one of AdoMet derivatives, methylthioadenosine (MTA). All this condensed information allows the reader to get a glimpse of the importance of AdoMet for all kind of cells, and hence of the only known route for its synthesis catalyzed by the MAT family of enzymes to which this article is committed.

2. Methionine adenosyltransferases

MAT enzymes use methionine and ATP to render AdoMet and triphosphate that is excised into pyrophosphate and inorganic phosphate in the second part of the reaction. This catalysis follows a S_N2 displacement mechanism, in which 95% of the P_i derives from the γ -phosphoryl group of ATP [19]. MATs need divalent cations (Mg^{2+}) for catalysis, and many of them are also activated by monovalent cations (K^+). AdoMet is needed for cell survival, and hence MATs have been found in almost every single organism (from *Mycoplasma genitalium* to mammals) except for a few parasites that obtain the compound from their hosts [20]. Sequences for the catalytic subunits are very well conserved between *Bacteria* and *Eukarya*, whereas *Archaea* express highly divergent forms in which catalytic amino acids are preserved [21]. All the enzymes of the family characterized to date are homo-oligomers, except for mammalian MAT II hetero-oligomers that consist of catalytic (α_2) and regulatory subunits (β) [22]. This β -subunit, however, is also able to interact with mammalian α_1 and *E. coli* catalytic subunits, as demonstrated upon its overexpression in cell culture lines and bacterial systems. Most of the oligomers found are tetramers, with two notable exceptions, the archaeal MATs and one mammalian isoenzyme known as MAT III that form dimeric associations [23].

Several MAT isoenzymes are expressed in diverse organisms (from *Eukarya* to *Bacteria*), the larger number of variants being found in plants [20]. Probably the most interesting, and best characterized, case is that found in mammals, where three isoenzymes exist, their main feature being the differences in K_m values for methionine exhibited by each isoform: MAT I (homo-tetramer) $\sim 100 \mu M$, MAT II (hetero-oligomer) $\sim 30 \mu M$ and MAT III (homodimer) $\sim 1 mM$ [5,

24]. These mammalian MATs are also regulated in a dissimilar way by the reaction product, thus whereas MAT I and II are inhibited by AdoMet, MAT III is activated [5, 25, 26]. Since their discovery it was thought that MAT I and III expression was restricted to normal liver, but recent papers showed first their expression in pancreas [27] and later in many other tissues [28]. On the other hand, MAT II was known to be ubiquitous, as well as the hepatic fetal form and the isoenzyme expressed in hepatoma [5]. Analysis of the β -subunit expression revealed that this subunit appears in most tissues and that its splicing variants show a differential expression pattern [29].

3. Human MAT genes and their mutations.

The human genome contains three MAT genes, *MAT1A*, *MAT2A* and *MAT2B* that encode for the two catalytic subunits, $\alpha 1$ and $\alpha 2$, and the regulatory β -subunit, respectively. The *MAT1A* gene (~20 kbp) localizes to the 10q22 human chromosome [30], the *MAT2A* gene (~6 kbp) to the 2p.1.1 chromosome [31] and the *MAT2B* gene (~6.8 kbp) was identified in the long arm of chromosome 5 at the interphase between 5q34 and 5q35.1 bands [32]. Both *MAT1A* and *MAT2A* genes consist of eight introns and nine exons that codify for proteins of 395 amino acids [33, 34]. On the other hand, the *MAT2B* gene consists of six introns and seven exons that encode for a protein of 335 residues [32].

Mutations in the *MAT1A* gene have been characterized in patients showing isolated persistent hypermethioninemia with methionine levels reaching 1.3 mM in some cases (35-fold over control levels) (Table 1)[35]. Most of these patients did not show important pathological symptoms, although a few cases of demyelination have been described [30, 36]. The mutations identified to date follow mostly a recessive autosomal inheritance trait, although Mendelian dominant inheritance for the G to A transition leading to the R264H^{h1} mutation has been described [37-39](Table 1). Some of the mutations reported led to early stop codons rendering subunits of 91, 184, 349, 350 and 386 residues [30, 35, 36, 40, 41]. The possibility of longer proteins has also been reported as a result of one mutation at the stop codon [42], and a change in the last nucleotide of exon III that alters the splice-donor site [35]. Some of these mutated

¹ The superscript indicates the species: rat (r), human (h), *E. coli* (c), *Methanococcus* (Mj)

MAT α 1 forms have been expressed in COS-1 and/or *E. coli* cells to study their activity and association state as has been reviewed elsewhere [34, 35, 39].

Neonatal screenings for early detection of metabolic alterations are carried out throughout the world. One of these procedures carried out in Galicia, a region in the northwest of Spain, revealed a high incidence of persistent hypermethioninemia among the galician population (1/23470 newborns), the most common mutation identified being *MAT1A* R264H^h [43]. However, to date no mutations in the human *MAT2A* and *MAT2B* genes have been reported, although the existence of splicing variants for *MAT2B* in hepatocellular carcinoma (HCC) and HepG2 cells has been shown [29]. Four variants have been described to date, the main splicing forms being V1 and V2 that differ in their transcriptional initiation site. These sites locate at positions -203 and -2372 from the ATG codon, respectively. Thus, V2 uses a different exon I and the resulting proteins diverge in the 20 initial amino acids of their N-terminals. In addition, V2a misses the first 51 bp of exon VII, whereas V2b lacks the information of exons III-VI. Available functional data have been obtained only with the V1 variant, and hence information concerning association of the new forms with the catalytic α 2 subunits, their effects on methionine affinity, or their putative actions on α 1 subunits is lacking.

4. MAT structure and impact of the human mutations.

Recently a review concerning the MAT structural data available has been published [23], and readers are referred to that publication for detailed structural information. Therefore, this section will focus on the location and potential structural effects of the human mutations described to date. The crystal structures that have been reported show common features concerning the α -subunit domain organization, the dimer association and the catalytic sites. The sequence of the α -subunits is arranged in three domains formed by non-consecutive stretches of the amino acid chain (Figure 3). Deletions originated by human *MAT1A* mutations include truncations leading of the loss of part of the C-terminal domain elements (386X and 350X) to proteins that lack information even for one complete domain of the three that are present in the wild type subunit (92X and 185X) (Figure 4). In addition, other truncated forms not only loss ~40% of the C-terminal domain, but also change the sequence of most of the remaining part of this domain, as well as of ~14% of the central domain (351X) (Figure 5). The longer α -subunits

resulting from the stop codon mutation, should in contrast contain the information to build the three wild type domains, but will have a C-terminal domain ~20% longer (X396Y-464X) (Figure 3). On the other hand, those derived from the mutation in the splice donor site should include a large change in the protein sequence, and hence their structure being drastically altered.

Two subunits associate to form the dimer through a large flat hydrophobic surface to which amino acids of the three domains contribute [44, 45](Figure 6). Thus, severe truncations (92X and 185X) will lack most of this interaction surface, whereas more moderate effects could be expected for those mutations rendering shorter C-terminal domains (350X and 386X). The exception should be the 827insG (351X) that may impose additional difficulties for association derived not only from the lack of part of the C-terminal domain, but also from the change in the sequence starting on residue 276 (Figure 5). The effect that a longer C-terminal (X396Y-464X) could have on the subunit association may range from no interference with the normal interaction pattern to steric hindrance of part of the interacting residues. Single amino acid substitutions detected in patients could also affect the interaction pattern indirectly, by changing the spatial orientation of the chains or directly by disrupting them. This last case could be that of L42P^h and L305P^h mutations that occur at α -helices H1 and H6, respectively. In addition to the large number of hydrophobic interactions linking monomers, there are a few polar bonds contributing to dimer stability [44]. Among the residues involved in this type of interactions is R264^h, the equivalent R265^r appearing bonded to E58^r and T263^r in the crystal structure of rat MAT I [44]. Several patients have the R264H^h or R261C^h mutations, which will clearly block interaction with E58^r that involves the side chain amino group of the arginine residue. Disruption of this bond seems will have important consequences for dimerization as judged from studies with the mutated recombinant proteins. Characterization of the recombinant R264H^h mutant showed that the protein is a monomer exhibiting tripolyphosphatase activity [46], although analogous mutants prepared by others and in MAT^c indicated its oligomeric association [39, 47].

The two active sites per dimer locate between both subunits that contribute the residues for substrate binding and catalysis [44, 48]. Such an organization thus needs the production of a precise arrangement that allows placing of the catalytic residues in the correct positions for catalysis to proceed. Essential residues have been identified by chemical modification and in crystal complexes including substrates (ATP and methionine) or their analogues (AMPPNP, L-

cisAMB, AEP)[23]. In most of the cases their role was later verified in recombinant proteins after site directed mutagenesis. Among them, F251^r against which methionine analogues are found and that locates at the initial position of a short loop in the active site [44]. No single mutations at key residues for AdoMet synthesis have been identified to date, although some substitutions may indirectly affect catalysis because of their sequence or spatial proximity to the catalytic residues, thus explaining the reductions in activity reported. In contrast, the human mutations involving R264^h directly perturb the phosphatase activity, as this residue has been show to orient the PPP_i chain for hydrolysis [47].

Interaction between dimers in the tetramer occurs through the central domains of the subunits. A few polar interactions are responsible of tetramerization, the number of which is lower in mammalian MATs than in the *E. coli* protein [44, 45]. Moreover, the interaction pattern seems quite different, the bacterial tetramer exhibiting a central interaction core, surrounded by a ring of interactions that in mammalian MAT I^r is lacking [49]. The existence of these additional bonds could be responsible for the higher stability exhibited by bacterial tetramers.

Other studies have shown cysteines as key residues for both MAT activity and dimer-dimer association in both rat and *E. coli* enzymes [50, 51]. The α 1-proteins contain 10 such residues per monomer, from which C121^r locates in a loop that has been proposed to regulate the access of substrates to the active site [44, 52]. Chemical modification of two cysteine residues/monomer in MAT I/III^r let to dissociation into inactive dimers [51, 53], a fact that has been further explored using single cysteine to serine mutants [54]. The results obtained indicated that the five residues located in the central domain (C35^r-C105^r) are key in dimer-dimer association, a result later supported by crystallographic data that showed the interface between dimers provided by this single domain. The sulfhydryl groups of residues C35^r and C61^r are facing each other and at disulfide bond distance, an important fact for oligomerization as it will be explained in the following sections [44, 49]. No human mutations at cysteine residues have been reported, although a couple of the substitutions identified to date include new cysteines at positions 264^h or 199^h [30, 35, 42], and the sequence change due to 827insG (351X^h) adds 6 cysteine residues more to the remaining C-terminal domain (Figure 5). The impact that inclusion of a larger number of this type of amino acid could have on protein folding may be responsible for the low activity exhibited by the recombinant mutants. The relevance of cysteines in α 2

proteins cannot be extrapolated from the results with $\alpha 1$ oligomers, since they differ in the cysteine content and lack equivalent residues at some positions in the central domain, among them C61^r.

5. Actual knowledge on MAT folding.

Most of the available data have been obtained *in vitro* using MAT I/III^r, *Bacillus subtilis* and *Methanococcus jannaschii* MATs in unfolding and refolding experiments using denaturants such as urea and temperature [55-57]. Here we will refer mainly to MAT I/III^r due to its high homology to the human enzyme. Refolding results indicated the need to populate an intermediate state to achieve the final active dimer and highlighted the importance of Mg²⁺ ions in the process [58]. Moreover, the last steps of the monomer refolding and their association need a reducing environment provided by DTT or appropriate GSH/GSSG molar ratios (10:1). Under these conditions fully active dimers were produced, although those obtained in the presence of GSH/GSSG contained a single disulfide bond (C35^r-C61^r) as well as several oxidized methionine residues [49]. Production of this single disulfide blocks the dimer-tetramer concentration-dependent equilibrium observed in the fully reduced forms, thus providing further evidence of the key role of cysteines in the central domain for association. The presence of copper during refolding has also been shown to reduce the production of active MAT $\alpha 1$ and MAT $\alpha 2$ oligomers, although no effect on the association state attained was observed [59].

Unfolding experiments revealed a rapid loss of AdoMet synthesis at very low urea concentrations, a process that preceded dimer dissociation [55]. In addition, structural information indicated that urea unfolding is a two-step process in which a monomeric intermediate (I) can be identified [55, 60]. The main characteristics of this state are: i) its lack of activity; ii) the conservation of a 70% of the secondary structure composition; and iii) some features of a molten globule. In addition, this intermediate exhibited reduced ANS binding capacity as compared to the native dimer, therefore suggesting exposure of a smaller hydrophobic surface to the solvent. The reversibility of MAT III^r folding allowed calculation of the free energy of the process that is 65.69 kJ/mol. Kinetic experiments showed later the existence of a second short-lived intermediate (I_k²) between I and the dimer that is supposed to be monomeric, although its precise association state has not been demonstrated [60]. Furthermore, tetramer to

dimer dissociation also occurs through a kinetic intermediate (I_k^1) that was detected following ANS fluorescence. This new state was suggested to be a dimer just before undergoing the conformational changes that differentiate MAT I and MAT III dimers [49]. The fact that this process can be followed by ANS fluorescence indicates that the dye binds near the tetramerization area, this site being identified as the $^{358}\text{PG}^{359}$ dipeptide^r and the $^{131}\text{VGA}^{134}$ stretch^r located to the beginning of the active site loop. The free energy of tetramerization was calculated to be 29.24 kJ/mol and that of the overall process 102.14 kJ/mol, thus showing that the main contribution to the oligomer stability derives from monomer-monomer association.

Recently the stability of the highly divergent MAT^{Mj} has been explored using urea and single tryptophan mutants at several secondary structure elements [56]. Despite its highly divergent sequence, MAT^{Mj} seems to preserve the topology and structural features of the rest of the family, and hence some data can be extrapolated. Thus, although MAT^{Mj} exhibits substantially higher stability than the mesophilic MATs, the structural elements more susceptible to urea denaturation are the exposed areas of three β -sheets at the flat contact surface between monomers, dimer dissociation requiring a wider perturbation involving the three domains of the molecule. In order to achieve higher stability the access of the denaturant to the monomer interface should be limited. Structural predictions show a tighter binding between monomers of MAT^{Mj} as compared to MAT^r [56], and crystal structures illustrate that the active site cavity is much wider in MAT^r than in the *E. coli* counterpart [23]. Extrapolation of these data to MAT^r suggests that urea access to analogous secondary structure elements is easier and that a larger portion of the β -sheets is exposed to the denaturant because of a wider active site. Thus, a more important perturbation of the β -sheets can be expected, and hence the rapid loss of activity observed in a protein with a low affinity for the substrate K_m^{Met} (~1 mM) and its dissociation at inferior urea concentrations.

On the other hand, thermal denaturation of MAT^r is an irreversible process in which changes in activity and structure occur in the range 37-55°C [61]. According to data obtained by two-dimensional infrared spectroscopy the first elements to undergo unfolding are the most solvent exposed, α -helices and β -turns. Exposure of hydrophobic residues and intersubunit hydrogen bonds are the second events that lead to final aggregation. These results could be a

consequence of two phenomena, dimer dissociation and monomer aggregation or direct aggregation of unfolded dimers.

The only *in vivo* folding data available refer to MAT^c, which has been identified among the substrates of the GroEL/GroES chaperonin system [62]. Several authors have indicated that the capacity of the active site cavity of this chaperonin would be able to admit proteins no larger than ~50 kDa, thus precluding the folding of MAT dimers in its inner space. The combined data available suggest that a monomeric intermediate (analogous to I) can be folded by the chaperonin, and such a monomer, according to ANS binding results, may expose a smaller hydrophobic surface to the solvent than the final dimer. Thus, this intermediate will need to accomplish some additional conformational changes to allow the establishment of the large number of hydrophobic contacts observed among monomers in the dimer. This association step may require additional chaperones that remain unidentified, the effects of copper accumulation on MAT oligomers suggesting a role for metallochaperones in this step [59].

6. Post-translational modifications.

The identification of post-translational modifications that could regulate MAT behavior has been the subject of study for several years, although the information obtained to date is quite limited. Most of the data relate to the redox regulation of the protein and have been attained with rat MAT I/III. Both *in vitro* and *in vivo* studies showed that MAT activity is decreased under oxidative conditions due to reductions in the GSH/GSSG ratio [16, 51, 63, 64]. Moreover, redox stress induced the accumulation of inactive dimers in animal models [65]. Analysis of the agents that led to such behavior revealed MAT inhibition by GSSG, H₂O₂ and NO, and related this inactivation to the production of an intrasubunit disulfide and C121^r hydroxylation or nitrosylation, respectively [16, 52, 66, 67]. The use of mutants and refolding systems allowed identification of C35^r and C61^r as the residues involved in the disulfide, and showed that production of this covalent modification blocks dimer-tetramer exchange [49, 68]. The presence of these two cysteines in the central domain suggests that the disulfide may contribute to the stabilization of the β -sheet through which interactions for tetramerization are established. Two additional cysteines exist in this sheet, C57^r and C69^r that according to the structural data appear at disulfide bond distance but with their sulfhydryl groups facing opposite directions [44].

Although not demonstrated yet, it is possible that folding intermediates in which anomalous disulfide patterns are established are favored during oxidative stress, and hence rendering inactive species that may or may not associate into dimers. The accumulation of inactive or poorly active dimers described during disease or intoxication processes that reduce the GSH/GSSG ratio may relate to the production of this kind of oxidized species, an aspect that remains unsolved.

Regarding nitrosylation and hydroxylation, the presence of C121^r in a flexible loop at the active site entrance, has led authors to postulate the putative role of this modification in the control of the access of substrates to the catalytic site. This modification has been suggested to block the loop in a closed conformation, thus impeding catalysis [52, 66, 67]. The presence of acid and basic residues in the proximity of the cysteine to be nitrosylated is a requirement for the modification to take place [69]. Such residues have been identified in rat MAT α 1 as D355^r, R357^r and R363^r and its key role further demonstrated by mutation to serine, a substitution that led to decreased NO modification. Some of the mutations identified in human persistent hypermethioninemia affect the equivalent R356^h residue introducing a glutamine or proline in this position, and change P357^h to leucine. Therefore, impairment in NO-induced regulation of MAT I/III activity is expected to occur in these patients. Both C121^r nitrosylation and the C35^r-C61^r disulfide provide regulatory mechanisms apparently restricted to α 1 oligomers, as the catalytic α 2 subunits lack the equivalent cysteine residues (G120 and A60).

In vitro refolding assays in the presence of GSH/GSSG allowed identification of methionine residues susceptible to oxidation (amino acids 20^r, 65^r, 139^r and 151^r) [49]. However, the impact of methionine modification on activity and oligomerization has not been explored further. The introduction of additional methionine residues due to human mutations (I322M^h) may provide the enzyme with a new oxidation target with higher affinity for modification. The location of this residue in the dimer structure and its contribution to the monomer-monomer stability may be affected by this substitution, rendering proteins with low activity as reported [34, 35].

Phosphorylation may be another mechanism through which MATs can be regulated [70]. Analysis of their sequences revealed several putative phosphorylation sites for a variety of kinases, although only PKC modification of MAT I/III at T342^r has been demonstrated *in vitro* [71]. One of the mutations identified to date in humans occurs at E344^h, residue that is substituted

by alanine. Such a change of charge near the phosphorylation site could be key for kinase recognition, thus altering the modification pattern. This effect could be also expected to occur in other human mutations that also locate next to putative phosphorylation sites, these include: R264H^h, K289N^h and G336R^h. However, both R264H^h and K289N^h may not be at truly phosphorylation sites due to their location at the active site cavity.

7. Alterations in MAT behavior in disease.

Changes in expression, oligomerization and MAT activity have been described in several pathologies and animal models of disease (Figure 7). Probably the largest amount of data published refers to hepatopathologies related to ethanol abuse and hepatomas, although results concerning leukemia and cognitive diseases are also available. Several authors have reported reductions in MAT1A mRNA levels during human alcoholic cirrhosis, although discrepancies about MAT2A transcript levels have been published. Thus, Avila et al. showed no induction of MAT2A by ethanol [72], whereas other studies reported increases in MAT2A expression, an effect mediated by TNF α [73]. In parallel, decreases in MAT activity and accumulation of dimers have been described that correlate with the corresponding reductions in AdoMet concentration [65, 74-77]. In contrast, differences in the effects on AdoHcy production among models occur, although the net effect in the methylation index (AdoMet/AdoHcy ratio), a decrease, is the same. Liver damage during ethanol consumption may be derived from the impairment of methylation reactions and GSH-dependent detoxification capacity. Reductions in GSH levels and increases in protein nitrosylation are known to take place in these cases, effects to which MAT I/III is susceptible. Other protein modifications caused by products of ethanol catabolism cannot be excluded, although this aspect has not been analyzed. Several reports have shown also that treatment with AdoMet attenuates ethanol liver injury [75], thus highlighting the importance of MAT function in the development of cirrhosis.

In the early 70s, Halpern et al. described the high dependence of human cancer cells on exogenous methionine for growth, whereas normal cells can use Hcy instead [78]. Therefore, the interest in understanding the alterations caused in the methionine cycle during carcinogenesis grew in order to search for useful drugs against this pathology. This search was conducted using a variety of carcinogens in animal models in which the effects exerted by the drugs in this

pathway were analyzed [79-85]. The results obtained showed a shift from MAT1A to MAT2A expression, reflected by reductions in MAT1A mRNA, protein and activity, and the corresponding increases in these parameters for MAT2A. The preferential expression of the $\alpha 2$ catalytic subunit renders a decrease in AdoMet levels that correlates with a global DNA hypomethylation [86]. This relationship with hepatocellular carcinoma (HCC) was further confirmed with the production of a MAT1A knockout mouse that spontaneously develops the disease [87], and reinforced by the observation that AdoMet therapy is efficient in preventing HCC [88]. In contrast, silencing of MAT2A expression in normal or MAT1A-overexpressing hepatoma cells produced cell death [89]. MAT2B provides a growth advantage to hepatoma cells, and its overexpression is normally associated with hepatic dysfunction [90]. In all these processes iNOS induction increases NO production leading not only to MAT I/III inactivation, and hence to a reduction in AdoMet concentration, but also to effects on several transcription factors that may control the switch among MATs [79].

Wilson's disease is another interesting pathology in which copper is accumulated in the liver due to mutations in the ATP7B transporter, thus leading to redox stress, among other effects. Several animal models of the disease exist and in one of them, Long Evans Cinnamon rats (LEC), changes in MAT activity and AdoMet levels were described at late stages of disease [91]. Several years later Delgado et al. examined the changes in the methionine cycle in this model but at early stages of copper accumulation, and showed changes in the expression pattern of the MAT isoenzymes [59]. In 9 week-old animals, a switch between MAT1A and MAT2A expression was already detected, but surprisingly MAT2B followed the opposite trend to MAT2A decreasing by 80%. Copper effects on MAT2B expression were also shown to rely on redox mechanisms in experiments carried out in cell culture. The changes in MAT1A expression correlated with decreases in protein, AdoHcy and GSH levels, the net result being an increase in the methylation index and a decrease in the GSH/GSSG ratio. As observed in other pathologies, copper accumulation also modified the MAT I/III ratio, but in this case reductions in dimer content were observed. Analysis of the effect of copper on MAT isoenzymes *in vitro* confirmed inhibition of the enzyme activity and showed the influence of this metal in folding of the subunits. Recombinant MAT $\alpha 2^h$ oligomer activity was more susceptible to metal inactivation than that of MAT $\alpha 1^f$ oligomers [59].

Patients suffering from several neurological diseases are known to display alterations in transmethylation reactions [92-96], and several animal models showed an association between methionine synthesis and/or MAT activity and development of myelopathies, ataxia and other related diseases [97-99]. Parkinson's patients show low AdoMet and AdoHcy levels in blood and increased erythrocyte MAT activity [95], although no relationship with age and duration of the disease has been reported. L-dopa treatment induces a short-term increase in hepatic and brain MAT expression and activity, as well as in AdoMet levels [100], but AdoMet depletion is observed in long therapies [101-105].

Currently, newborn screenings for the detection of hypermethioninemia are carried out all over the world. Most of the cases identified are due to defects in CBS, fumaryl acetoacetate hydrolase (tyrosinemia type I) or liver disease, however in a small number of patients this alteration is due to mutations in the *MAT1A* or *GNMT* genes [105]. The first patient with isolated persistent hypermethioninemia due to *MAT1A* mutation was reported in 1974 [106], and ever since new mutations have been identified, a summary of which is included in Table 1. Many patients are asymptomatic, but in a few cases neurological defects have been noticed. The most severe cases present demyelination and correspond to mutations that introduce early stop codons in the *MAT1A* ORF, leading to subunits of ~350 amino acids. One of these patients was treated with AdoMet and an improvement in demyelination was reported, thus suggesting that these symptoms derive from low AdoMet production [94]. In addition, former experiments using cycloleucine, a MAT inhibitor, in rats showed development of myelin abnormalities that were prevented by AdoMet [107]. All these data together and the absence of such symptoms in patients exhibiting shorter forms of the $\alpha 1$ protein led Hazelwood et al. [36] to propose the hetero-oligomerization hypothesis, which will be discussed in the last section of this chapter to explain the origin of the disease. This hypothesis presented a conceptual problem at the time of its proposal that was related to the restricted expression pattern known for MATI/III (considered hepatic only) and alterations in the nervous system, where only MAT II was known to exist.

8. MAT tissular distribution and subcellular localization.

Early data on MAT tissue-specific expression derived mostly from activity measurements carried out in samples from different tissues at two methionine concentrations (to distinguish

among MAT isoenzymes with different K_m^{Met}) and in the presence of DMSO (a known activator of MAT III). The same is true for the subcellular distribution that was analyzed in fractionation experiments. All these data established the extrahepatic presence of MAT II, together with the hepatic expression of MAT I/III in normal tissues. This postulate was reassessed in the last decade using Northern and Western blot and real time PCR. The compiled results confirmed the broad MAT2A and MAT2B expression [90] and a wide distribution for MAT1A that exceeds normal adult liver [28]. The expression levels correlated with early results: i) very high for MAT1A in liver followed by pancreas [28]; ii) high for MAT2B in spleen, heart, lung and very low in normal adult liver [90]; and iii) high in extrahepatic tissues, fetal liver and hepatoma for MAT2A [5]. Subcellular distribution was also thought to be restricted to the cytosol and fluorescence microscopy confirmed this localization for the β subunit [90]. However, recent studies by immunohistochemistry, confocal fluorescence microscopy, subcellular fractionation and western blot showed MAT α 1 in the cytosol of hepatocytes and pancreatic cells but also in the nucleus of almost every cell type analyzed [28]. Thus, the question arises as to which may be the biological role for this distribution.

Nuclear MAT α 1^r was mainly monomeric, although a small amount of active tetramers could be detected in this compartment in liver [28]. The protein colocalized with nuclear matrix markers and both nuclear distribution and matrix localization were independent of AdoMet synthesis capacity, the inactive F251D^r mutant showing the same pattern than the wild type protein. Basic residues in the C-terminal domain were shown to be involved in the nucleocytoplasmic distribution, and two partially overlapping areas were identified that are implicated in localization. One area delimited by amino acids 313^r, 368^r, 369^r and 392^r was related to cytosolic retention, whereas that comprised by residues 340^r, 344^r and 393^r was linked to nuclear localization. The subcellular distribution of a truncated protein at residue 351X^r, analogous to some of the mutants detected in human patients with hypermethioninemia, was also examined. This shorter form appeared mainly in the nucleus and colocalized with the nuclear matrix marker SC-35. The use of mutants showing preferential nuclear or cytosolic localization allowed correlation of nuclear MAT α 1^r distribution with increases in specific epigenetic modifications (H3K27 trimethylation) [28]. This result suggested the need for the presence of active nuclear MAT α 1 oligomers to guarantee specific methylations, and opened the possibility

of additional unknown functions for the nuclear monomers. Moreover, identification of the areas responsible for nucleocytoplasmic distribution close to the *in vitro* phosphorylated T342^r residue deserve additional studies to determine the role that such modification may have in the control of MAT subcellular localization. Additionally, both the nucleocytoplasmic distribution and its putative control by phosphorylation may be altered in patients with mutations in these areas, such as those related to E344^h and G336^h residues which induce charge changes at the molecular surface (Table 1).

9. Hazelwood's hypothesis of MAT hetero-oligomerization in demyelination.

The observation of demyelination exclusively in patients with *MAT1A* mutations leading to subunits ~350 amino acids long, together with the improvement observed in the symptoms of one of this patients upon AdoMet treatment let Hazelwood et al. propose that truncated $\alpha 1$ subunits may hetero-oligomerize with $\alpha 2$ monomers sequestering them in an inactive oligomer, and hence producing a decrease in AdoMet levels [36]. This decreased concentration of the methyl donor will lead to the corresponding lack of methylation products, among them phosphatidylcholine and creatine, important for neural sheath [108] and neural structure [109]. Thus, administration of AdoMet would allow recovery of normal intracellular levels of the methyl donor, and hence the improvement observed in the patient symptoms [94]. This hypothesis was postulated in 1998 when only the MAT^c crystal structure was available [45], and the importance of the R264 residue in dimerization was known. Preservation of this arginine and the high homology among $\alpha 1$ and $\alpha 2$ human sequence (84%) seemed enough to consider hetero-oligomerization plausible. Now when more MAT structures are available [23], it is known that monomers may have slightly different orientations between each other in different species [44], and the impact of these truncations on the monomer subunit and the intersubunit interactions in the dimer can be reexamined. Thus, truncated subunits will lack approximately half of the C-terminal domain, specifically the area mostly related to the monomer surface. The impact this deficiency will have in folding of the remaining C-terminal domain structure, including the β -sheet that participates in monomer-monomer contacts, is unknown. However, this fact will force a rearrangement of the region to hide amino acids that will become otherwise exposed. Moreover, the 351X mutant not only suffers the truncation of part of this domain, but also a change in its

sequence that affects a ~15% of the central domain. This means an almost completely different C-terminal domain, and hence making preservation of its structure and interaction pattern unlikely (Figure 5).

As mentioned in previous sections, the last years have also seen some *in vitro* folding studies that showed the need of populating a monomeric intermediate I to attain the final active structure. The appropriate conformation of this intermediate will allow the final changes in the subunit structure and the association into active oligomers. The importance of this intermediate may require chaperonin assisted folding, as deduced from the finding of MAT^c as a substrate of the GroEL/GroES system [62]. To date, it is not known if truncated MATs will achieve a similar intermediate state allowing association with the $\alpha 2$ subunits. Moreover, if additional chaperones are needed to catalyze the last folding and association steps, the possibility exists that the modifications concerning the C-terminal domain may preclude recognition or achievement of a structure resembling at least part of the wild type structure (N-terminal and central domains). Even if the truncated monomer is able to oligomerize, two association scenarios can be considered: i) correct hetero-oligomerization, which should render a dimer with one complete active site (from the two in the molecule); and ii) an hetero-oligomerization pattern different from that in the native dimer, an alteration that will be of special importance for the active sites that locate between monomers. Structures of *E. coli* and mammalian MATs are almost identical, and hence overexpression of the truncated forms in bacteria is expected to produce hetero-oligomers with MAT^c. These experiments were performed and no MAT activity was reported by Chamberlin et al. [30]. In our hands, overexpression of a 351X^r mutant led to inclusion body production, thus suggesting incorrect folding of this type of subunit [28].

Another problem of Hazelwood's hypothesis at the time of its proposal was derived from the identification of MAT $\alpha 1$ oligomers only in liver. Now that expression of *MAT1A* has been proven in other tissues [28], this problem no longer exists, although new aspects have to be considered. First, the putative interaction of inappropriately folded truncated species with proteins other than the $\alpha 2$ subunits should be taken into account. Such anomalous interactions may be responsible for the observed symptoms. Second, MAT $\alpha 1$ expression in extrahepatic tissues occurs mainly in the cell nucleus, where most of the protein appears as monomers. A truncated form similar to that of patients with demyelination showed its preferential accumulation

in the nucleus in several cell types, thus suggesting that the effects observed may derive from the functions MAT is exerting in that particular compartment. To date we only know that nuclear accumulation of MAT α 1 correlates with H3K27 trimethylation, an epigenetic modification related to gene repression. Accumulation of truncated mutants in the nucleus will either favor this modification (i. e. repressing myelin related genes) or interfere with this methylation due to anomalous binding of MAT α 1 truncated species that are incorrectly folded. Finally, the hypothesis did not consider α 2 β interactions. No data exist about how these subunits interact, neither of the role of spliced β -subunit variants, and hence of the effect that α 2-truncated α 1 hetero-oligomerization may exert in recognition of the regulatory subunit.

CONCLUSION

The knowledge on MAT structure, catalytic mechanism and regulation has increased enormously during the last decades. However, this accumulated information has provided no clue to the relationship between some *MAT1A* mutations and the demyelination observed in patients expressing the corresponding truncated forms. The main aspects that remain to be clarified to understand this relationship include: i) the structure of the truncated protein subunits; ii) its oligomerization abilities with either α 2 and β subunits; iii) understanding the *in vivo* folding pathway for MATs and the chaperones/chaperonines involved; iv) the effect of nuclear accumulation of truncated subunits in cellular behavior (i.e. myelin production); and, v) elucidation of the nuclear functions of MAT α 1, and hence of its alterations due to truncations. In addition, the putative existence of MAT I/III moonlighting related to its presence in to date new subcellular locations, and hence the effect that mutations could have on these additional functions cannot be underestimated. Thus, the number of questions related to MATs that await an answer is increasing, despite the large effort made to date to get insight the knowledge of the relationship among this family of enzymes and disease.

ACKNOWLEDGEMENTS

C. Pérez was a postdoctoral fellow of the UNAM-CSIC Program. This work was supported by grants of the Ministerio de Ciencia e Innovación (BFU2008-00666 and BFU2009-08977 to MAP).

REFERENCES

- 1- Cantoni, G. L. (1951) Activation of methionine for transmethylation. *J. Biol. Chem.* 189, 745-754.
- 2- Cantoni, G. L. (1953) S-adenosylmethionine; a new intermediate formed enzymatically from L-methionine and adenosinetriphosphate. *J. Biol. Chem.* 204, 403-416.
- 3- Iwig, D. F. & Booker, S. J. (2004) Insight into the polar reactivity of the onium chalcogen analogues of S-adenosyl-L-methionine. *Biochemistry.* 43, 13496-13509.
- 4- Fontecave, M., Atta, M. & Mulliez, E. (2004) S-adenosylmethionine: nothing goes to waste. *Trends Biochem. Sci.* 29, 243-249.
- 5- Mato, J. M., Alvarez, L., Ortiz, P. & Pajares, M. A. (1997) S-adenosylmethionine synthesis: molecular mechanisms and clinical implications. *Pharmacol. Ther.* 73, 265-280.
- 6- Cantoni, G. L. (1975) Biological methylation: selected aspects. *Annu. Rev. Biochem.* 44, 435-451.
- 7- Chen, X., Schauder, S., Potier, N., Van Dorsselaer, A., Pelczer, I., Bassler, B. L. & Hughson, F. M. (2002) Structural identification of a bacterial quorum-sensing signal containing boron. *Nature* 415, 545-549.
- 8- Nishimura, S., Taya, Y., Kuchino, Y. & Oashi, Z. (1974) Enzymatic synthesis of 3-(3-amino-3-carboxypropyl)uridine in *Escherichia coli* phenylalanine transfer RNA: transfer of the 3-amino-acid-3-carboxypropyl group from S-adenosylmethionine. *Biochem. Biophys. Res. Commun.* 57, 702-708.
- 9- Sufrin, J. R., Finckbeiner, S. & Oliver, C. M. (2009) Marine-derived metabolites of S-adenosylmethionine as templates for new anti-infectives. *Mar Drugs.* 7, 401-434.
- 10- Frey, P. A., Hegeman, A. D. & Ruzicka, F. J. (2008) The Radical SAM Superfamily. *Crit. Rev. Biochem. Mol. Biol.* 43, 63-88.
- 11- Eisenberg, M. A. & Stoner, G. L. (1971) Biosynthesis of 7,8-diaminopelargonic acid, a biotin intermediate, from 7-keto-8-aminopelargonic acid and S-adenosyl-L-methionine. *J. Bacteriol.* 108, 1135-1140.
- 12- Van Lanen, S. G. & Iwata-Reuyl, D. (2003) Kinetic mechanism of the tRNA-modifying enzyme S-adenosylmethionine:tRNA ribosyltransferase-isomerase (QueA). *Biochemistry* 42, 5312-5320.
- 13- Dolnick, B. J., Angelino, N. J., Dolnick, R. & Sufrin, J. R. (2003) A novel function for the rTS gene. *Cancer Biol. Ther.* 2, 364-369.

14- Mudd, S. H. & Poole, J. R. (1975) Labile methyl balances for normal humans on various dietary regimens. *Metabolism Clin. Exp.* 24, 721-735.

15- Pajares, M. A. & Perez-Sala, D. (2006) Betaine homocysteine S-methyltransferase: just a regulator of homocysteine metabolism? *Cell. Mol. Life Sci.* 63, 2792-2803.

16- Pajares, M. A., Duran, C., Corrales, F., Pliego, M. M. & Mato, J. M. (1992) Modulation of rat liver S-adenosylmethionine synthetase activity by glutathione. *J. Biol. Chem.* 267, 17598-17605.

17- Luka, Z., Mudd, S. H. & Wagner, C. (2009) Glycine N-methyltransferase and regulation of S-adenosylmethionine levels. *J. Biol. Chem.* 284, 22507-22511.

18- Ansorena, E., Garcia-Trevijano, E. R., Martinez-Chantar, M. L., Huang, Z. Z., Chen, L., Mato, J. M., Iraburu, M., Lu, S. C. & Avila, M. A. (2002) S-adenosylmethionine and methylthioadenosine are antiapoptotic in cultured rat hepatocytes but proapoptotic in human hepatoma cells. *Hepatology* 35, 274-280.

19- Markham, G. D., Hafner, E. W., Tabor, C. W. & Tabor, H. (1980) S-Adenosylmethionine synthetase from *Escherichia coli*. *J. Biol. Chem.* 255, 9082-9092.

20- Sanchez-Perez, G. F., Bautista, J. M. & Pajares, M. A. (2004) Methionine adenosyltransferase as a useful molecular systematics tool revealed by phylogenetic and structural analyses. *J. Mol. Biol.* 335, 693-706.

21- Lu, Z. J. & Markham, G. D. (2002) Enzymatic properties of S-adenosylmethionine synthetase from the archaeon *Methanococcus jannaschii*. *J. Biol. Chem.* 277, 16624-16631.

22- Kotb, M. & Geller, A. M. (1993) Methionine adenosyltransferase: structure and function. *Pharmacol. Ther.* 59, 125-143.

23- Markham, G. D. & Pajares, M. A. (2009) Structure-function relationships in methionine adenosyltransferases. *Cell. Mol. Life Sci.* 66, 636-648.

24- Kotb, M. & Kredich, N. M. (1985) S-Adenosylmethionine synthetase from human lymphocytes. Purification and characterization. *J. Biol. Chem.* 260, 3923-3930.

25- De La Rosa, J., Ostrowski, J., Hryniewicz, M. M., Kredich, N. M., Kotb, M., LeGros, H. L., Jr., Valentine, M. & Geller, A. M. (1995) Chromosomal localization and catalytic properties of the recombinant alpha subunit of human lymphocyte methionine adenosyltransferase. *J. Biol. Chem.* 270, 21860-21868.

26- LeGros, H. L., Jr., Geller, A. M. & Kotb, M. (1997) Differential regulation of methionine adenosyltransferase in superantigen and mitogen stimulated human T lymphocytes. *J. Biol. Chem.* 272, 16040-16047.

27- Lu, S. C., Gukovsky, I., Lugea, A., Reyes, C. N., Huang, Z. Z., Chen, L., Mato, J. M., Bottiglieri, T. & Pandol, S. J. (2003) Role of S-adenosylmethionine in two experimental models of pancreatitis. *FASEB J.* 17, 56-58.

28- Reytor, E., Perez-Miguelsanz, J., Alvarez, L., Perez-Sala, D. & Pajares, M. A. (2009) Conformational signals in the C-terminal domain of methionine adenosyltransferase I/III determine its nucleocytoplasmic distribution. *FASEB J.* 23, 3347-3360.

29- Yang, H., Ara, A. I., Magilnick, N., Xia, M., Ramani, K., Chen, H., Lee, T. D., Mato, J. M. & Lu, S. C. (2008) Expression pattern, regulation, and functions of methionine adenosyltransferase 2beta splicing variants in hepatoma cells. *Gastroenterology* 134, 281-291.

30- Chamberlin, M. E., Ubagai, T., Mudd, S. H., Wilson, W. G., Leonard, J. V. & Chou, J. Y. (1996) Demyelination of the brain is associated with methionine adenosyltransferase I/III deficiency. *J. Clin. Invest.* 98, 1021-1027.

31- Kotb, M., Mudd, S. H., Mato, J. M., Geller, A. M., Kredich, N. M., Chou, J. Y. & Cantoni, G. L. (1997) Consensus nomenclature for the mammalian methionine adenosyltransferase genes and gene products. *Trends Genet.* 13, 51-52.

32- LeGros, L., Halim, A. B., Chamberlin, M. E., Geller, A. & Kotb, M. (2001) Regulation of the human MAT2B gene encoding the regulatory beta subunit of methionine adenosyltransferase, MAT II. *J. Biol. Chem.* 276, 24918-24924.

33- Halim, A. B., LeGros, L., Chamberlin, M. E., Geller, A. & Kotb, M. (2001) Regulation of the human MAT2A gene encoding the catalytic alpha 2 subunit of methionine adenosyltransferase, MAT II: gene organization, promoter characterization, and identification of a site in the proximal promoter that is essential for its activity. *J. Biol. Chem.* 276, 9784-9791.

34- Ubagai, T., Lei, K. J., Huang, S., Mudd, S. H., Levy, H. L. & Chou, J. Y. (1995) Molecular mechanisms of an inborn error of methionine pathway. Methionine adenosyltransferase deficiency. *J. Clin. Invest.* 96, 1943-1947.

35- Chamberlin, M. E., Ubagai, T., Mudd, S. H., Thomas, J., Pao, V. Y., Nguyen, T. K., Levy, H. L., Greene, C., Freehauf, C. & Chou, J. Y. (2000) Methionine adenosyltransferase I/III deficiency: novel mutations and clinical variations. *Am. J. Hum. Genet.* 66, 347-355.

36- Hazelwood, S., Bernardini, I., Shotelersuk, V., Tangerman, A., Guo, J., Mudd, H. & Gahl, W. A. (1998) Normal brain myelination in a patient homozygous for a mutation that encodes a severely truncated methionine adenosyltransferase I/III. *Am. J. Med. Genet.* 75, 395-400.

37- Nagao, M. & Oyanagi, K. (1997) Genetic analysis of isolated persistent hypermethioninemia with dominant inheritance. *Acta Paediatr. Jap.* 39, 601-606.

38- Blom, H. J., Davidson, A. J., Finkelstein, J. D., Luder, A. S., Bernardini, I., Martin, J. J., Tangerman, A., Trijbels, J. M., Mudd, S. H., Goodman, S. I. & et al. (1992) Persistent hypermethioninaemia with dominant inheritance. *J. Inherit. Metab. Dis.* 15, 188-197.

39- Chamberlin, M. E., Ubagai, T., Mudd, S. H., Levy, H. L. & Chou, J. Y. (1997) Dominant inheritance of isolated hypermethioninemia is associated with a mutation in the human methionine adenosyltransferase 1A gene. *Am. J. Hum. Genet.* 60, 540-546.

40- Mudd, S. H., Levy, H. L., Tangerman, A., Boujet, C., Buist, N., Davidson-Mundt, A., Hudgins, L., Oyanagi, K., Nagao, M. & Wilson, W. G. (1995) Isolated persistent hypermethioninemia. *Am. J. Hum. Genet.* 57, 882-892.

41- Kim, S. Z., Santamaria, E., Jeong, T. E., Levy, H. L., Mato, J. M., Corrales, F. J. & Mudd, S. H. (2002) Methionine adenosyltransferase I/III deficiency: two Korean compound heterozygous siblings with a novel mutation. *J. Inherit. Metab. Dis.* 25, 661-671.

42- Chien, Y. H., Chiang, S. C., Huang, A. & Hwu, W. L. (2005) Spectrum of hypermethioninemia in neonatal screening. *Early Hum. Dev.* 81, 529-533.

43- Couce, M. L., Boveda, M. D., Castineiras, D. E., Corrales, F. J., Mora, M. I., Fraga, J. M. & Mudd, S. H. (2008) Hypermethioninaemia due to methionine adenosyltransferase I/III (MAT I/III) deficiency: Diagnosis in an expanded neonatal screening programme. *J. Inherit. Metab. Dis.* doi 10.1007/s10545-008-0811-3.

44- Gonzalez, B., Pajares, M. A., Hermoso, J. A., Alvarez, L., Garrido, F., Sufrin, J. R. & Sanz-Aparicio, J. (2000) The crystal structure of tetrameric methionine adenosyltransferase from rat liver reveals the methionine-binding site. *J. Mol. Biol.* 300, 363-375.

45- Takusagawa, F., Kamitori, S., Misaki, S. & Markham, G. D. (1996) Crystal structure of S-adenosylmethionine synthetase. *J. Biol. Chem.* 271, 136-147.

46- Perez Mato, I., Sanchez del Pino, M. M., Chamberlin, M. E., Mudd, S. H., Mato, J. M. & Corrales, F. J. (2001) Biochemical basis for the dominant inheritance of hypermethioninemia associated with the R264H mutation of the MAT1A gene. A monomeric methionine adenosyltransferase with tripolyphosphatase activity. *J. Biol. Chem.* 276, 13803-13809.

47- Reczkowski, R. S., Taylor, J. C. & Markham, G. D. (1998) The active-site arginine of S-adenosylmethionine synthetase orients the reaction intermediate. *Biochemistry* 37, 13499-13506.

48- Gonzalez, B., Pajares, M. A., Hermoso, J. A., Guillerm, D., Guillerm, G. & Sanz-Aparicio, J. (2003) Crystal structures of methionine adenosyltransferase complexed with substrates and products reveal the methionine-ATP recognition and give insights into the catalytic mechanism. *J. Mol. Biol.* 331, 407-416.

49- Sanchez-Perez, G. F., Gasset, M., Calvete, J. J. & Pajares, M. A. (2003) Role of an intrasubunit disulfide in the association state of the cytosolic homo-oligomer methionine adenosyltransferase. *J. Biol. Chem.* 278, 7285-7293.

50- Markham, G. D. & Satishchandran, C. (1988) Identification of the reactive sulfhydryl groups of S-adenosylmethionine synthetase. *J. Biol. Chem.* 263, 8666-8670.

51- Corrales, F., Cabrero, C., Pajares, M. A., Ortiz, P., Martin-Duce, A. & Mato, J. M. (1990) Inactivation and dissociation of S-adenosylmethionine synthetase by modification of sulfhydryl groups and its possible occurrence in cirrhosis. *Hepatology* 11, 216-222.

52- Avila, M. A., Mingorance, J., Martinez-Chantar, M. L., Casado, M., Martin-Sanz, P., Bosca, L. & Mato, J. M. (1997) Regulation of rat liver S-adenosylmethionine synthetase during septic shock: role of nitric oxide. *Hepatology* 25, 391-396.

53- Pajares, M. A., Corrales, F. J., Ochoa, P. & Mato, J. M. (1991) The role of cysteine-150 in the structure and activity of rat liver S-adenosyl-L-methionine synthetase. *Biochem. J.* 274, 225-229.

54- Mingorance, J., Alvarez, L., Sanchez-Gongora, E., Mato, J. M. & Pajares, M. A. (1996) Site-directed mutagenesis of rat liver S-adenosylmethionine synthetase. Identification of a cysteine residue critical for the oligomeric state. *Biochem. J.* 315, 761-766.

55- Gasset, M., Alfonso, C., Neira, J. L., Rivas, G. & Pajares, M. A. (2002) Equilibrium unfolding studies of the rat liver methionine adenosyltransferase III, a dimeric enzyme with intersubunit active sites. *Biochem. J.* 361, 307-315.

56- Garrido, F., Alfonso, C., Taylor, J. C., Markham, G. D. & Pajares, M. A. (2009) Subunit association as the stabilizing determinant for archaeal methionine adenosyltransferases. *Biochim. Biophys. Acta* 1794, 1082-1090.

57- Kamarthapu, V., Rao, K. V., Srinivas, P. N., Reddy, G. B. & Reddy, V. D. (2008) Structural and kinetic properties of *Bacillus subtilis* S-adenosylmethionine synthetase expressed in *Escherichia coli*. *Biochim. Biophys. Acta* 1784, 1949-1958.

58- Lopez-Vara, M. C., Gasset, M. & Pajares, M. A. (2000) Refolding and characterization of rat liver methionine adenosyltransferase from *Escherichia coli* inclusion bodies. *Prot. Expr. Purif.* 19, 219-226.

59- Delgado, M., Perez-Miguelsanz, J., Garrido, F., Rodriguez-Tarduchy, G., Perez-Sala, D. & Pajares, M. A. (2008) Early effects of copper accumulation on methionine metabolism. *Cell. Mol. Life Sci.* 65, 2080-2090.

- 60- Sanchez del Pino, M. M., Perez-Mato, I., Sanz, J. M., Mato, J. M. & Corrales, F. J. (2002) Folding of dimeric methionine adenosyltransferase III: identification of two folding intermediates. *J. Biol. Chem.* 277, 12061-12066.
- 61- Iloro, I., Chehin, R., Goni, F. M., Pajares, M. A. & Arrondo, J. L. (2004) Methionine adenosyltransferase alpha-helix structure unfolds at lower temperatures than beta-sheet: a 2D-IR study. *Biophys. J.* 86, 3951-3958.
- 62- Houry, W. A., Frishman, D., Eckerskorn, C., Lottspeich, F. & Hartl, F. U. (1999) Identification of in vivo substrates of the chaperonin GroEL. *Nature* 402, 147-154.
- 63- Corrales, F., Gimenez, A., Alvarez, L., Caballeria, J., Pajares, M. A., Andreu, H., Pares, A., Mato, J. M. & Rodes, J. (1992) S-adenosylmethionine treatment prevents carbon tetrachloride-induced S-adenosylmethionine synthetase inactivation and attenuates liver injury. *Hepatology* 16, 1022-1027.
- 64- Corrales, F., Ochoa, P., Rivas, C., Martin-Lomas, M., Mato, J. M. & Pajares, M. A. (1991) Inhibition of glutathione synthesis in the liver leads to S-adenosyl-L-methionine synthetase reduction. *Hepatology* 14, 528-533.
- 65- Cabrero, C., Duce, A. M., Ortiz, P., Alemany, S. & Mato, J. M. (1988) Specific loss of the high-molecular-weight form of S-adenosyl-L-methionine synthetase in human liver cirrhosis. *Hepatology* 8, 1530-1534.
- 66- Avila, M. A., Corrales, F. J., Ruiz, F., Sanchez-Gongora, E., Mingorance, J., Carretero, M. V. & Mato, I. M. (1998) Specific interaction of methionine adenosyltransferase with free radicals. *BioFactors* 8, 27-32.
- 67- Sanchez-Gongora, E., Ruiz, F., Mingorance, J., An, W., Corrales, F. J. & Mato, J. M. (1997) Interaction of liver methionine adenosyltransferase with hydroxyl radical. *FASEB J.* 11, 1013-1019.
- 68- Mingorance, J., Alvarez, L., Pajares, M. A. & Mato, J. M. (1997) Recombinant rat liver S-adenosyl-L-methionine synthetase tetramers and dimers are in equilibrium. *Int. J. Biochem. Cell Biol.* 29, 485-491.
- 69- Perez-Mato, I., Castro, C., Ruiz, F. A., Corrales, F. J. & Mato, J. M. (1999) Methionine adenosyltransferase S-nitrosylation is regulated by the basic and acidic amino acids surrounding the target thiol. *J. Biol. Chem.* 274, 17075-17079.
- 70- Pajares, M. A., Corrales, F., Duran, C., Mato, J. M. & Alvarez, L. (1992) How is rat liver S-adenosylmethionine synthetase regulated? *FEBS Lett.* 309, 1-4.
- 71- Pajares, M. A., Duran, C., Corrales, F. & Mato, J. M. (1994) Protein kinase C phosphorylation of rat liver S-adenosylmethionine synthetase: dissociation and production of an active monomer. *Biochem. J.* 303, 949-955.
- 72- Avila, M. A., Berasain, C., Torres, L., Martin-Duce, A., Corrales, F. J., Yang, H., Prieto, J., Lu, S. C., Caballeria, J., Rodes, J. & Mato, J. M. (2000) Reduced mRNA abundance of the main enzymes involved in methionine metabolism in human liver cirrhosis and hepatocellular carcinoma. *J. Hepatol.* 33, 907-914.
- 73- Yang, H., Sadda, M. R., Yu, V., Zeng, Y., Lee, T. D., Ou, X., Chen, L. & Lu, S. C. (2003) Induction of human methionine adenosyltransferase 2A expression by tumor necrosis factor alpha. Role of NF-kappa B and AP-1. *J. Biol. Chem.* 278, 50887-50896.
- 74- Lu, S. C., Huang, Z. Z., Yang, H., Mato, J. M., Avila, M. A. & Tsukamoto, H. (2000) Changes in methionine adenosyltransferase and S-adenosylmethionine homeostasis in alcoholic rat liver. *Am. J. Physiol. Gastrointest. Liver Physiol.* 279, G178-185.

75- Lieber, C. S., Casini, A., DeCarli, L. M., Kim, C. I., Lowe, N., Sasaki, R. & Leo, M. A. (1990) S-adenosyl-L-methionine attenuates alcohol-induced liver injury in the baboon. *Hepatology* 11, 165-172.

76- Villanueva, J. A. & Halsted, C. H. (2004) Hepatic transmethylation reactions in micropigs with alcoholic liver disease. *Hepatology* 39, 1303-1310.

77- Lee, T. D., Satta, M. R., Mendler, M. H., Bottiglieri, T., Kanel, G., Mato, J. M. & Lu, S. C. (2004) Abnormal hepatic methionine and glutathione metabolism in patients with alcoholic hepatitis. *Alcoholism Clin. Exp. Res.* 28, 173-181.

78- Halpern, B. C., Clark, B. R., Hardy, D. N., Halpern, R. M. & Smith, R. A. (1974) The effect of replacement of methionine by homocystine on survival of malignant and normal adult mammalian cells in culture. *Proc. Natl. Acad. Sci. USA.* 71, 1133-1136.

79- Simile, M. M., Pagnan, G., Pastorino, F., Brignole, C., De Miglio, M. R., Muroi, M. R., Asara, G., Frau, M., Seddaiu, M. A., Calvisi, D. F., Feo, F., Ponzoni, M. & Pascale, R. M. (2005) Chemopreventive N-(4-hydroxyphenyl)retinamide (fenretinide) targets deregulated NF- κ B and Mat1A genes in the early stages of rat liver carcinogenesis. *Carcinogenesis* 26, 417-427.

80- Okada, G., Sawai, Y., Teraoka, H. & Tsukada, K. (1979) Differential effects of dimethylsulfoxide on S-adenosylmethionine synthetase from rat liver and hepatoma. *FEBS Lett.* 106, 25-28.

81- Huang, Z. Z., Mato, J. M., Kanel, G. & Lu, S. C. (1999) Differential effect of thioacetamide on hepatic methionine adenosyltransferase expression in the rat. *Hepatology* 29, 1471-1478.

82- Tsukada, K. & Okada, G. (1980) S-Adenosylmethionine synthetase isozyme patterns from rat hepatoma induced by N-2-fluorenylacetylamide. *Biochem. Biophys. Res. Commun.* 94, 1078-1082.

83- Horikawa, S., Kobayashi, Y., Sugiyama, T., Terashima, H., Wada, K., Tsukada, K. & Hirokawa, S. (1993) Expression of non-hepatic-type S-adenosylmethionine synthetase isozyme in rat hepatomas induced by 3'-methyl-4-dimethylaminoazobenzene. *FEBS Lett.* 334, 69-71.

84- Liao, M. C., Chang, C. F. & Becker, F. F. (1979) Alteration of S-adenosylmethionine synthetases during chemical hepatocarcinogenesis and in resulting carcinomas. *Cancer Res.* 39, 2113-2119.

85- Liang, C. R., Leow, C. K., Neo, J. C., Tan, G. S., Lo, S. L., Lim, J. W., Seow, T. K., Lai, P. B. & Chung, M. C. (2005) Proteome analysis of human hepatocellular carcinoma tissues by two-dimensional difference gel electrophoresis and mass spectrometry. *Proteomics* 5, 2258-2271.

86- Yang, H., Huang, Z. Z., Zeng, Z., Chen, C., Selby, R. R. & Lu, S. C. (2001) Role of promoter methylation in increased methionine adenosyltransferase 2A expression in human liver cancer. *Am. J. Physiol. Gastrointest. Liver Physiol.* 280, G184-190.

87- Martinez-Chantar, M. L., Corrales, F. J., Martinez-Cruz, L. A., Garcia-Trevijano, E. R., Huang, Z. Z., Chen, L., Kanel, G., Avila, M. A., Mato, J. M. & Lu, S. C. (2002) Spontaneous oxidative stress and liver tumors in mice lacking methionine adenosyltransferase 1A. *FASEB J.* 16, 1292-1294.

88- Garcea, R., Daino, L., Pascale, R., Simile, M. M., Puddu, M., Frassetto, S., Cozzolino, P., Seddaiu, M. A., Gaspa, L. & Feo, F. (1989) Inhibition of promotion and persistent nodule

growth by S-adenosyl-L-methionine in rat liver carcinogenesis: role of remodeling and apoptosis. *Cancer Res.* 49, 1850-1856.

89- Cai, J., Mao, Z., Hwang, J. J. & Lu, S. C. (1998) Differential expression of methionine adenosyltransferase genes influences the rate of growth of human hepatocellular carcinoma cells. *Cancer Res.* 58, 1444-1450.

90- Martinez-Chantar, M. L., Garcia-Trevijano, E. R., Latasa, M. U., Martin-Duce, A., Fortes, P., Caballeria, J., Avila, M. A. & Mato, J. M. (2003) Methionine adenosyltransferase II beta subunit gene expression provides a proliferative advantage in human hepatoma. *Gastroenterology* 124, 940-948.

91- Shimizu, K., Abe, M., Yokoyama, S., Takahashi, H., Sawada, N., Mori, M. and Tsukada, K. (1990) Decreased activities of S-adenosylmethionine synthetase isozymes in hereditary hepatitis in Long-Evans rats. *Life Sci.* 46, 1837-1842.

92- Gomes Trolin, C., Regland, B. & Orelund, L. (1995) Decreased methionine adenosyltransferase activity in erythrocytes of patients with dementia disorders. *Eur. Neuropsychopharmacol.* 5, 107-114.

93- Gomes-Trolin, C., Yassin, M., Gottfries, C. G., Regland, B., Grenfeldt, B., Hallman, J., Prince, J. & Orelund, L. (1998) Erythrocyte and brain methionine adenosyltransferase activities in patients with schizophrenia. *J. Neural Transm.* 105, 1293-1305.

94- Surtees, R., Leonard, J. & Austin, S. (1991) Association of demyelination with deficiency of cerebrospinal-fluid S-adenosylmethionine in inborn errors of methyl-transfer pathway. *Lancet* 338, 1550-1554.

95- Cheng, H., Gomes-Trolin, C., Aquilonius, S. M., Steinberg, A., Lofberg, C., Ekblom, J. & Orelund, L. (1997) Levels of L-methionine S-adenosyltransferase activity in erythrocytes and concentrations of S-adenosylmethionine and S-adenosylhomocysteine in whole blood of patients with Parkinson's disease. *Exp. Neurol.* 145, 580-585.

96- Regland, B., Johansson, B. V., Grenfeldt, B., Hjelmgren, L. T. & Medhus, M. (1995) Homocysteinemia is a common feature of schizophrenia. *J. Neural Trans.* 100, 165-169.

97- Lee, C. C., Surtees, R. & Duchon, L. W. (1992) Distal motor axonopathy and central nervous system myelin vacuolation caused by cycloleucine, an inhibitor of methionine adenosyltransferase. *Brain.* 115, 935-955.

98- Scott, J. M. (1992) Folate-vitamin B12 interrelationships in the central nervous system. *Proc. Nutr. Soc.* 51, 219-224.

99- Scott, J. M., Molloy, A. M., Kennedy, D. G., Kennedy, S. & Weir, D. G. (1994) Effects of the disruption of transmethylation in the central nervous system: an animal model. *Acta Neurol. Scand.* 154, 27-31.

100- Zhao, W. Q., Latinwo, L., Liu, X. X., Lee, E. S., Lamango, N. & Charlton, C. G. (2001) L-dopa upregulates the expression and activities of methionine adenosyl transferase and catechol-O-methyltransferase. *Exp. Neurol.* 171, 127-138.

101- Melamed, E., Globus, M., Friedlender, E. & Rosenthal, J. (1983) Chronic L-dopa administration decreases striatal accumulation of dopamine from exogenous L-dopa in rats with intact nigrostriatal projections. *Neurology* 33, 950-953.

102- Hunter, K. R., Shaw, K. M., Laurence, D. R. & Stern, G. M. (1973) Sustained levodopa therapy in parkinsonism. *Lancet* 2, 929-931.

103- Marsden, C. D. & Parkes, J. D. (1977) Success and problems of long-term levodopa therapy in Parkinson's disease. *Lancet* 1, 345-349.

104- Fahn, S. & Calne, D. B. (1978) Considerations in the management of parkinsonism. *Neurology* 28, 5-7.

105- Mudd, S. H., Cerone, R., Schiaffino, M. C., Fantasia, A. R., Minniti, G., Caruso, U., Lorini, R., Watkins, D., Matiaszuk, N., Rosenblatt, D. S., Schwahn, B., Rozen, R., LeGros, L., Kotb, M., Capdevila, A., Luka, Z., Finkelstein, J. D., Tangerman, A., Stabler, S. P., Allen, R. H. & Wagner, C. (2001) Glycine N-methyltransferase deficiency: a novel inborn error causing persistent isolated hypermethioninaemia. *J. Inherit. Metab. Dis.* 24, 448-464.

106- Gaull, G. E. & Tallan, H. H. (1974) Methionine adenosyltransferase deficiency: new enzymatic defect associated with hypermethioninemia. *Science* 186, 59-60.

107- Bianchi, R., Calzi, F., Savaresi, S., Sciarretta-Birollo, R., Bellasio, R., Tsankova, V. & Tacconi, M. T. (1999) Biochemical analysis of myelin lipids and proteins in a model of methyl donor pathway deficit: effect of S-adenosylmethionine. *Exp. Neurol.* 159, 258-266.

108- Norton, W. T. (1984) Recent advances in myelin biochemistry. *Annals NY Acad. Sci.* 436, 5-10.

109- Stockler, S., Isbrandt, D., Hanefeld, F., Schmidt, B. & von Figura, K. (1996) Guanidinoacetate methyltransferase deficiency: the first inborn error of creatine metabolism in man. *Am. J. Hum. Genet.* 58, 914-922.

110- Linnebank, M., Lagler, F., Muntau, A. C., Roschinger, W., Olgemoller, B., Fowler, B. & Koch, H. G. (2005) Methionine adenosyltransferase (MAT) I/III deficiency with concurrent hyperhomocysteinaemia: two novel cases. *J. Inherit. Metab. Dis.* 28, 1167-1168.

111- Finkelstein, J. D., Kyle, W. E. & Martin, J. J. (1975) Abnormal methionine adenosyltransferase in hypermethioninemia. *Biochem. Biophys. Res. Commun.* 66, 1491-1497.

112- Gaull, G. E., Tallan, H. H., Lonsdale, D., Przyrembel, H., Schaffner, F. & von Bassewitz, D. B. (1981) Hypermethioninemia associated with methionine adenosyltransferase deficiency: clinical, morphologic, and biochemical observations on four patients. *J. Pediatr.* 98, 734-741.

Reviewed by:

George D. Markham. Institute for Cancer Research, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA.

Dolores Pérez-Sala. Centro de Investigaciones Biológicas (CSIC), Ramiro de Maeztu 9, 28040 Madrid, Spain.

FIGURE LEGENDS

Figure 1. Reactions involving S-adenosylmethionine. The figure summarizes the reactions in which S-adenosylmethionine participates in any kind of cell organized according to the group that is transferred in each case. S-adenosylhomocysteine (SAH) and S-adenosylmethioninamine are intermediates in some of these processes.

Figure 2. The methionine cycle in mammalian liver. The first step of methionine metabolism is the synthesis of S-adenosylmethionine by methionine adenosyltransferases (*MATs*). This compound is used as methyl donor by a large number of methyltransferases (*MTase*), and among them glycine N-methyltransferase (*GNMT*), leading to methylated acceptors and S-adenosylhomocysteine. This demethylated compound is degraded by S-adenosylhomocysteine hydrolase (*SAHH*), in the only reversible reaction of the cycle, to render adenosine and homocysteine. Methionine can then be resynthesized from homocysteine by methylations catalyzed by methionine synthase (*MS*) and betaine homocysteine methyltransferase (*BHMT*) that use 5-methyltetrahydrofolate (MTHF) and betaine as methyl donors, respectively. MTHF is synthesized by methylene tetrahydrofolate reductase (*MTHFR*) an enzyme inhibited by S-adenosylmethionine. Homocysteine can enter also the trans-sulfuration pathway, where it is converted to cystathionine by cystathionine β -synthase (*CBS*).

Figure 3. Organization of the MAT amino acid sequence among structural domains and impact of human deletions and sequence extensions. The figure shows the sequence stretches involved in each domain, the percentage of contribution in each case appearing below. The impact of human mutations leading to truncated or extended monomers is also shown. Changes from the wild type sequence are indicated in magenta.

Figure 4. Impact of truncations in the monomer structure. The figure shows the structural elements of each domain preserved in the truncated human MATs; N-terminal (blue), central (red) and C-terminal (green) domains.

Figure 5. The human 351X mutant changes a large stretch of its C-terminal sequence. The 827insG in the human *MAT1A* ORF leads not only to an early stop codon, but also to a complete change in the reading frame, and therefore in the sequence starting on residue 276. Comparison of the resulting sequence and the wild type is shown in the upper part of the figure, whereas the lower part depicts the effect of the sequence changes in the side chains (residues 271-stop) is depicted. The last common amino acids (271-275) appear in cyan and blue for the wild type and 351X C-terminals, respectively.

Figure 6. The human MAT α 1 dimer. The figure shows the expected structure for the human α 1 dimer created by mutation in the rat sequence of the 1QM4 pdb file; the sequences of both proteins are 95% identical. Monomer A surface appears in blue, the areas of contact with monomer B (salmon) being shown in gray. The three β -sheets of monomer B (one contributed per domain) appear oriented against the contact areas of monomer A. The arrow indicates the entrance to one of the active sites of the molecule.

Figure 7. Summary of the knowledge on MAT regulation. The scheme represents the different levels (mRNA, protein and activity) reported for MAT regulation during disease or under several treatments. Black dashed arrows indicate increases, whereas red dashed arrows stand for decreases in any of the parameters examined. Abbreviations correspond to: superantigen staphylococcal enterotoxin B (SEB); S-adenosylmethionine (AdoMet); methylthioadenosine (MTA); phytohemagglutinin (PHA); interleukin 2 (IL-2); interleukin 6 (IL-6); lipopolysaccharide (LPS); buthionine sulfoximine (BSO); oxidized glutathione (GSSG); 3-morpholinopyridone (SIN-1); S-nitrosoglutathione (GSNO).

TABLE 1

Mutations in the *MAT1A* gene detected in human persistent hypermethioninemia

Exon	Gene mutation	Protein mutation ⁷	inheritance	Recombinant protein characteristics ³	Liver activity ⁶	Ref.
I	C65T	S22L	HO ¹			110]
II	G113A	S38N	CHE ²	No activity ⁵	68%	35, 111
	T125C	L42P	HO			110
	C164A	A55D	CHE	17% ⁴		34
III	G205A	G69S				42
	255delCA	92X	CHE	No activity ⁵		35, 111
		G98S	HO	100% activity ^{4,5}		35
V	C426T	A142	CHE			34
	539insTG	185X	HO, CHE		7%	30, 36
VI	C595T	R199C	CHE, HO	10% activity ⁵		30
	C745T	R249W				42
VII	G791A	R264H		<1% activity ^{4,5} monomer	low	35, 37-39, 42, 43
	G791T	R264C	CHE	No activity ⁵		35
	C790T	R264C				42
	G867T	K289N				42
	G870A	V290	CHE			34
	T914C	L305P	CHE	25% ⁴		34
	827insG	351X	HO	No activity ⁵		30
VIII	T966G	I322M	HO, CHE	21% ^{4,5}		34, 35
	G1006A	G336R	CHE	23% activity ⁵		35
	A1031C	E344A	CHE	12% ⁵		35
	1043,1044del	350X	HO	No activity ⁵		30, 40
	G1067A	R356Q	CHE	53% activity ⁵	low	30, 112
		R356P				42
	C1070T	P357L	CHE	31% ⁴		34, 42
IX	T1131C	Y377	CHE			34
	G1132A	G378S	CHE	0.1% activity ⁵		30, 41, 112
	G1161A	W387X	CHE, HO	75% activity ⁵ dimer		41
	G1188T	X396YfsX464				42

¹HO, homozygosis²CHE, compound heterozygosis³Mutant activity levels versus wt protein upon COS-1⁴ or *E. coli*⁵ overexpression⁶Measured in liver biopsies⁷Residue change in the resulting protein




Figure 1




Figure 2







Figure 3




wt




387X



350X




185X




92X

Figure 4

wt	251	VIGGPQGDAG	261	VTGRKIIVDT	271	YGGWGAHGGG	281	AFSGKDYTKV
351X	251	VIGGPQGDAG	261	VTGRKIIVDT	271	YGGWGSWWW	281	GLLWEGLHQG
wt	291	DRSAAYAARW	301	VAKSLVKAGL	311	CRRVLVQVSY	321	AIGVAEPLSI
351X	291	RPLSCICCP	301	GGQVSGESRA	311	LPESACPGFL	321	CHWCGRAAVH
wt	331	SIFTYGTSQK	341	TERELLDVVH	351	KNFDLRPGVI	361	VRDLDLKKPI
351X	331	FHLHLRNLSE	341	DRARAAGCGA	350			
wt	371	YQKTACYGHF	381	GRSEFPWEVP	391	RKLVF	395	



wt



351X

Figure 5




Figure 6




Figure 7